Financial Performance - The company's revenue for Q1 2025 was ¥301,066,807.47, a decrease of 26.39% compared to ¥409,023,327.96 in the same period last year[4] - Net profit attributable to shareholders was ¥91,384,342.59, down 39.77% from ¥151,726,071.70 year-on-year[4] - The total profit for the current period is 121,839,114.94, down 39.5% from 201,855,917.71 in the previous period[22] - The operating profit for the current period is 121,564,366.63, a decline of 39.7% from 201,497,325.69 in the previous period[22] - The net profit for the current period is 91,384,342.59, a decrease of 39.8% compared to 151,726,071.70 in the previous period[22] - Basic and diluted earnings per share for the current period are both 0.23, down from 0.38 in the previous period[22] Cash Flow - The net cash flow from operating activities was -¥66,164,752.80, a decline of 151.78% compared to ¥127,782,897.03 in the previous year[4] - The cash flow from operating activities shows a net outflow of -66,164,752.80, compared to a net inflow of 127,782,897.03 in the previous period[24] - Cash inflow from investment activities is 650,640,918.41, with a net cash flow of 116,472,903.16, contrasting with a net outflow of -43,749,580.19 in the previous period[24] - The cash flow from financing activities resulted in a net outflow of -434,508,092.77, compared to -200,946.18 in the previous period[24] - The company received cash from investment recovery amounting to 610,000,000.00 during the current period[24] - The company reported other cash inflows related to operating activities of 67,801,825.79, an increase from 34,835,161.18 in the previous period[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,964,918,300.73, a decrease of 1.97% from ¥6,084,668,329.15 at the end of the previous year[4] - The total liabilities decreased to CNY 211,161,758.25, down 50.0% from CNY 422,296,129.26 in the previous period[20] - The company's cash and cash equivalents at the end of the period were CNY 1,763,687,214.23, down from CNY 1,838,840,251.92 at the beginning of the period[19] - Inventory increased to CNY 188,611,153.63, up 17.6% from CNY 160,291,765.15 in the previous period[19] - The company's retained earnings rose to CNY 2,373,780,428.02, an increase from CNY 2,282,396,085.43 in the previous period[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,211[13] - Zhang Liguan holds 84.41% of shares, totaling 337,720,000 shares[13] - The top 10 shareholders include Harbin Sanlian Pharmaceutical Co., Ltd. with 18,000,000 shares, representing 4.50%[13] - The total number of restricted shares at the beginning of the period was 341,485,000, with 2,900,000 shares released and 1,950,000 shares added, resulting in 340,535,000 restricted shares at the end[16] - The company has a plan for the release of restricted shares, with specific dates for unlocking[15] Research and Development - Research and development expenses increased by 61.60% to ¥9,792,953.74, reflecting the company's commitment to enhancing R&D investment[9] - Research and development expenses rose to CNY 9,792,953.74, an increase of 61.4% compared to CNY 6,060,108.47 in the previous period[21] Government Subsidies - The company received government subsidies amounting to ¥42,866,221.65, contributing to other income growth of 775.51%[9] Other Financial Metrics - The weighted average return on equity decreased to 1.60%, down 1.07% from 2.67% in the previous year[4] - The company reported a net profit of CNY 43,655,154.72 from other income, significantly higher than CNY 4,986,273.07 in the previous period[21] - Total operating costs increased to CNY 237,454,375.39, up 7.4% from CNY 220,697,574.24 in the previous period[21] Share Transactions - The company has not disclosed any related party transactions among the top shareholders[14] - The company has not participated in any share lending or borrowing activities during the reporting period[14] - The company has a total of 947,300 shares held by shareholder Han Jianhua through a margin trading account[14] - The company has a total of 769,200 shares held by shareholder Wang Jianqiang through a margin trading account[14] - The company has a total of 482,000 shares held by shareholder Li Bin through a margin trading account[14]
敷尔佳(301371) - 2025 Q1 - 季度财报